TABLE 2.
Baseline results.
| Parameters | TGP | CGP | GP |
|---|---|---|---|
| LYs | 4.991 | 4.751 | 2.976 |
| QALYs | 2.778 | 2.630 | 1.670 |
| Total cost $ | 48,525 | 46,293 | 26,680 |
| ICER $/LY | 10,842 a | 10,904 a | — |
| 10,321 b | |||
| ICER $/QALY | 19,726 a | 20,438 a | — |
| 15,103 b | |||
| WTP $/QALY | 37,653 | ||
a
Compared to GP.
b
Compared to CGP.
Abbreviation: TGP, toripalimab plus gemcitabine and cisplatin; CGP, camrelizumab plus gemcitabine and cisplatin; GP, gemcitabine and cisplatin; ICER, incremental cost-effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year; WTP, willingness-to-pay.